Fig. 5
From: Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
Efficacy of CUDC-907 in the proteasome inhibitor-resistant myeloma cells. a KMS-11/BTZ cells were treated with the indicated concentrations of CUDC-907 for 72 h. The effect of CUDC-907 treatment on cellular growth was evaluated. *P < 0.05 vs. control. b KMS-11/BTZ cells were treated with CUDC-907 for 24 h. Total cell lysates were evaluated by immunoblotting. Results represent the mean of three independent experiments. c Myeloma cells were treated with the indicated concentration of CUDC-907 for 24 h. Total cell lysates were evaluated by immunoblotting. d Myeloma cells were treated with CUDC-907 for 24 h and measured using the 20S Proteasome Assay Kit. *P < 0.05 vs. control. e, f, g The effect of CUDC-907 treatment on cellular growth (e) and cytotoxicity (f) and caspase 3/7 activity (g) was evaluated. *P < 0.05 compared to carfilzomib and CUDC-907 co-treated cells. h Myeloma cells were treated with the indicated concentrations of carfilzomib and/or CUDC-907 for 24 h. Total cell lysates were evaluated by immunoblotting.